| scholarly article | Q13442814 |
| P50 | author | Daved H. Fremont | Q16195537 |
| Soila Sukupolvi-Petty | Q46150876 | ||
| Theodore C Pierson | Q59939112 | ||
| Theodore Oliphant | Q81871283 | ||
| Grant E Nybakken | Q117206710 | ||
| Michael J Engle | Q117206711 | ||
| Anantha Marri | Q117206712 | ||
| Michael S. Diamond | Q28051146 | ||
| P2093 | author name string | Qing Xu | |
| Christopher A Nelson | |||
| Bat-El Lachmi | |||
| Udy Olshevsky | |||
| P2860 | cites work | Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes | Q24289053 |
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| New mouse model for dengue virus vaccine testing | Q27469339 | ||
| Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. | Q27469591 | ||
| Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E | Q27469788 | ||
| Complement activation is required for induction of a protective antibody response against West Nile virus infection | Q27469834 | ||
| Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein | Q27469915 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus | Q27472711 | ||
| West Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and Infection | Q27472821 | ||
| Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc Receptor-Dependent and -Independent Mechanisms | Q27472823 | ||
| Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein | Q27472922 | ||
| B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. | Q27473103 | ||
| A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites | Q27473104 | ||
| Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
| Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. | Q40769543 | ||
| Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies | Q40781926 | ||
| Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection | Q40798801 | ||
| Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses | Q40810691 | ||
| Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody | Q41178513 | ||
| The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein | Q42980684 | ||
| Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report | Q42994017 | ||
| Neutralizing monoclonal antibodies against Russian strain of the West Nile virus | Q42995688 | ||
| Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies | Q43030485 | ||
| Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages | Q43034693 | ||
| Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus | Q27473288 | ||
| West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody | Q27477479 | ||
| Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites | Q27477542 | ||
| Pathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion | Q27477543 | ||
| Crystal Structure of the West Nile Virus Envelope Glycoprotein | Q27477648 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| A Critical Role for Induced IgM in the Protection against West Nile Virus Infection | Q27485124 | ||
| Partial Genetic Characterization of West Nile Virus Strains, New York State, 2000 | Q27487791 | ||
| Structure of the dengue virus envelope protein after membrane fusion | Q27643009 | ||
| Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation | Q27643140 | ||
| The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution | Q27730234 | ||
| Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines | Q28249533 | ||
| Structural basis of West Nile virus neutralization by a therapeutic antibody | Q29618168 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| Conformational changes of the flavivirus E glycoprotein | Q29618170 | ||
| Structure of West Nile Virus | Q29618173 | ||
| Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica | Q29618177 | ||
| Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM | Q29618178 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody | Q29619712 | ||
| Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display | Q31108093 | ||
| Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses | Q33208947 | ||
| The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. | Q33824681 | ||
| Antibody prophylaxis and therapy for flavivirus encephalitis infections. | Q34498847 | ||
| Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein | Q37596501 | ||
| Human Dengue antibodies against structural and nonstructural proteins | Q39507601 | ||
| The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection | Q40313211 | ||
| A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection | Q40344161 | ||
| Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice | Q40344535 | ||
| Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. | Q40467368 | ||
| Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. | Q40468928 | ||
| Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells | Q40505862 | ||
| Characterization of neutralizing antibodies to West Nile virus | Q40509400 | ||
| Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice | Q40556192 | ||
| Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies | Q40609346 | ||
| Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. | Q40698415 | ||
| Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection | Q40718122 | ||
| Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever | Q40748542 | ||
| Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection | Q40763034 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| West Nile virus | Q158856 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 12149-59 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | |
| P478 | volume | 80 |
| Q24705237 | A CRISPR screen defines a signal peptide processing pathway required by flaviviruses |
| Q93101098 | A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy |
| Q24261408 | A Mouse Model of Zika Virus Pathogenesis |
| Q27488367 | A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes |
| Q33802834 | A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein |
| Q27314576 | A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy |
| Q33323464 | A decade of yeast surface display technology: where are we now? |
| Q33954392 | A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus |
| Q35531326 | A fusion-loop antibody enhances the infectious properties of immature flavivirus particles |
| Q37012203 | A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection |
| Q40164185 | A multiplex ELISA-based protein array for screening diagnostic antigens and diagnosis of Flaviviridae infection |
| Q33934227 | A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice |
| Q34132718 | A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus |
| Q41864274 | A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: a case study using monoclonal antibodies against the West Nile virus E protein |
| Q40038769 | A novel mechanism of antibody-mediated enhancement of flavivirus infection |
| Q28241909 | A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates |
| Q28740740 | A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus |
| Q34044677 | A review of West Nile and Usutu virus co-circulation in Europe: how much do transmission cycles overlap? |
| Q28804076 | A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis |
| Q94452248 | Amino acid 159 of the envelope protein affects viral replication and T-cell infiltration by West Nile virus in intracranial infection |
| Q38866173 | An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection |
| Q36305202 | Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells |
| Q97521587 | Anti-dengue Vaccines: From Development to Clinical Trials |
| Q36255087 | Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis |
| Q34202698 | Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2 |
| Q36931818 | Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo |
| Q27486409 | Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II |
| Q34776746 | Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe |
| Q34999617 | Antibody-mediated neutralization of flaviviruses: a reductionist view |
| Q33743491 | Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design |
| Q38008644 | Approaches for the development of rapid serological assays for surveillance and diagnosis of infections caused by zoonotic flaviviruses of the Japanese encephalitis virus serocomplex |
| Q37673123 | B cell response and mechanisms of antibody protection to West Nile virus |
| Q35567408 | B-cell responses during primary and secondary dengue virus infections in humans |
| Q27649830 | Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins |
| Q33839001 | Bioinformatics in new generation flavivirus vaccines |
| Q36318652 | Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress |
| Q83225458 | Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics |
| Q30145645 | Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies |
| Q57464788 | Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus |
| Q35220195 | Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population |
| Q27487953 | Closing the door on flaviviruses: Entry as a target for antiviral drug design |
| Q34261496 | Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition |
| Q27485131 | Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific Manner |
| Q27490423 | Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus |
| Q35607988 | Complement-mediated neutralization of dengue virus requires mannose-binding lectin |
| Q30250932 | Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope |
| Q27488305 | Crystal Structure of Dengue Virus Type 1 Envelope Protein in the Postfusion Conformation and Its Implications for Membrane Fusion |
| Q27676100 | Crystal Structure of the Japanese Encephalitis Virus Envelope Protein |
| Q59349995 | Crystal structure of Usutu virus envelope protein in the pre-fusion state |
| Q37694852 | DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice. |
| Q64229721 | DNA-Protein Vaccination Strategy Does Not Protect from Challenge with African Swine Fever Virus Armenia 2007 Strain |
| Q38157397 | DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. |
| Q27654848 | Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity |
| Q35152251 | Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis |
| Q27480795 | Defining Limits of Treatment with Humanized Neutralizing Monoclonal Antibody for West Nile Virus Neurological Infection in a Hamster Model |
| Q33425879 | Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection |
| Q26824712 | Degrees of maturity: the complex structure and biology of flaviviruses |
| Q61795509 | Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice |
| Q38614539 | Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past. |
| Q28278881 | Dengue virus life cycle: viral and host factors modulating infectivity |
| Q27490436 | Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype |
| Q47558158 | Development of Antibody Therapeutics against Flaviviruses |
| Q27491049 | Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys |
| Q47269331 | Development of envelope protein antigens to serologically differentiate Zika from dengue virus infection |
| Q35092308 | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies |
| Q92867102 | Efficient transplacental IgG transfer in women infected with Zika virus during pregnancy |
| Q33911897 | Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice |
| Q38758003 | Enhancing dengue virus maturation using a stable furin over-expressing cell line |
| Q63248501 | Envelope protein glycosylation mediates Zika virus pathogenesis |
| Q27486109 | Enzyme-Linked Immunosorbent Assays Using Novel Japanese Encephalitis Virus Antigen Improve the Accuracy of Clinical Diagnosis of Flavivirus Infections |
| Q35998781 | Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions. |
| Q40225317 | Evaluation of the European tick-borne encephalitis vaccine against Omsk hemorrhagic fever virus |
| Q47558877 | Evaluation of the protective ability of plasma from Japanese individuals against mosquito-borne viral infections |
| Q38017388 | Flaviviruses and flavivirus vaccines |
| Q35818688 | Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. |
| Q37123259 | Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection |
| Q36950014 | Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody |
| Q38722930 | GRP78 Is an Important Host Factor for Japanese Encephalitis Virus Entry and Replication in Mammalian Cells |
| Q38721146 | Generation and characterization of a monoclonal antibody against duck Tembusu virus envelope protein |
| Q39208408 | Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes |
| Q27485481 | Genetically delivered antibody protects against West Nile virus |
| Q36172100 | Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity |
| Q39668466 | Genotype-specific neutralization and protection by antibodies against dengue virus type 3. |
| Q36245225 | Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing |
| Q39444247 | Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature |
| Q52360423 | Human IFIT3 Modulates IFIT1 RNA Binding Specificity and Protein Stability. |
| Q34529911 | Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus |
| Q27488791 | Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step |
| Q27486404 | Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo |
| Q27488243 | Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens |
| Q27489953 | Identification of Continuous Human B-Cell Epitopes in the Envelope Glycoprotein of Dengue Virus Type 3 (DENV-3) |
| Q52564640 | Identification of Glucose-Regulated Protein 78 (GRP78) as a Receptor in BHK-21 Cells for Duck Tembusu Virus Infection. |
| Q27927982 | Identification of a New Broadly Cross-reactive Epitope within Domain III of the Duck Tembusu Virus E Protein |
| Q54236847 | Identification of determinants that mediate binding between tembusu virus and the cellular receptor heat shock protein A9. |
| Q35982791 | Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions |
| Q33951093 | Identification of two linear B-cell epitopes from West Nile virus NS1 by screening a phage-displayed random peptide library |
| Q24701741 | Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses |
| Q27677965 | Immature and Mature Dengue Serotype 1 Virus Structures Provide Insight into the Maturation Process |
| Q40340971 | Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice |
| Q27489515 | Impact of Quaternary Organization on the Antigenic Structure of the Tick-Borne Encephalitis Virus Envelope Glycoprotein E |
| Q36697323 | Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses |
| Q33945441 | In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection |
| Q27484980 | Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus |
| Q40307795 | Infection and activation of human peripheral blood monocytes by dengue viruses through the mechanism of antibody-dependent enhancement. |
| Q40124689 | Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine |
| Q29051494 | Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection |
| Q27315772 | Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification |
| Q41857868 | Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody |
| Q28114614 | Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination |
| Q27485890 | Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization |
| Q23032973 | Mechanism and significance of cell type-dependent neutralization of flaviviruses |
| Q28472177 | Mechanisms of GII.4 norovirus persistence in human populations |
| Q40049416 | Modified mRNA Vaccines Protect against Zika Virus Infection |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q38045381 | Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans |
| Q27488337 | Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection |
| Q83231499 | Molecular organization and dynamics of the fusion protein Gc at the hantavirus surface |
| Q24684689 | Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention |
| Q33401149 | Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice |
| Q54265465 | Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. |
| Q39563308 | Neutralization escape variant of West Nile virus associated with altered peripheral pathogenicity and differential cytokine profile |
| Q27490987 | Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient |
| Q38335402 | Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q27490925 | PCP Consensus Sequences of Flaviviruses: Correlating Variance with Vector Competence and Disease Phenotype |
| Q37851212 | Partial maturation: an immune-evasion strategy of dengue virus? |
| Q40302703 | Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection |
| Q34548508 | Physicochemical property consensus sequences for functional analysis, design of multivalent antigens and targeted antivirals |
| Q40078229 | Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. |
| Q35531167 | Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms |
| Q47553138 | Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo. |
| Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
| Q61053973 | Pre-Existing Dengue Immunity Drives a DENV-Biased Plasmablast Response in ZIKV-Infected Patient |
| Q40423085 | Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine |
| Q40248409 | Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus |
| Q40799861 | Protective immune response against newly emerging goose tembusu virus infection induced by immunization with a recombinant envelope protein |
| Q34480254 | Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast |
| Q35840849 | Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections |
| Q36411126 | Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis |
| Q58733184 | Screening and identification of B-cell epitopes within envelope protein of tembusu virus |
| Q23925011 | Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host |
| Q36226190 | Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes. |
| Q27674417 | Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope |
| Q40056291 | Structural Basis of Zika Virus-Specific Antibody Protection |
| Q27677962 | Structural Changes in Dengue Virus When Exposed to a Temperature of 37 C |
| Q27488364 | Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development |
| Q100431443 | Structural and antigenic investigation of Usutu virus envelope protein domain III |
| Q27490283 | Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody |
| Q31131254 | Structural, antigenic, and evolutionary characterizations of the envelope protein of newly emerging Duck Tembusu Virus |
| Q34120070 | Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. |
| Q27674868 | Structure of the St. Louis Encephalitis Virus Postfusion Envelope Trimer |
| Q36192685 | Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation |
| Q63246530 | The Conserved Molecular Determinants of Virulence in Dengue Virus |
| Q27491317 | The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 |
| Q37252899 | The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses |
| Q35850813 | The Molecular Epidemiology and Evolution of Murray Valley Encephalitis Virus: Recent Emergence of Distinct Sub-lineages of the Dominant Genotype 1. |
| Q27488224 | The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection |
| Q37448171 | The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity |
| Q35531189 | The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases |
| Q36842733 | The molecular basis of antibody-mediated neutralization of West Nile virus |
| Q39207889 | The nucleolar helicase DDX56 redistributes to West Nile virus assembly sites |
| Q34386384 | The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein |
| Q27486421 | The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus |
| Q27487955 | The structural immunology of antibody protection against West Nile virus |
| Q35069160 | The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein |
| Q34607919 | Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. |
| Q27487124 | Toll-Like Receptor 3 Has a Protective Role against West Nile Virus Infection |
| Q27485031 | Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes |
| Q90911603 | VISTA is an acidic pH-selective ligand for PSGL-1 |
| Q34594111 | Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination |
| Q60046445 | Viral-Induced Enhanced Disease Illness |
| Q66679530 | West Nile Virus and Usutu Virus Co-Circulation in Europe: Epidemiology and Implications |
| Q89511215 | West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors |
| Q40290346 | West Nile virus: characterization and diagnostic applications of monoclonal antibodies |
| Q27487333 | West Nile virus–induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons |
| Q33299124 | Yeast surface display for protein engineering and characterization |
| Q24050115 | Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise |
| Q38156674 | Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. |
| Q40037821 | Zika virus has oncolytic activity against glioblastoma stem cells |
Search more.